Abstract:Atropisomeric anilides have received tremendous attention as a novel class of chiral compounds possessing restricted rotation around an N-aryl chiral axis. However, in sharp contrast to the well-studied synthesis of biaryl atropisomers, the catalytic asymmetric synthesis of chiral anilides remains a daunting challenge, largely due to the higher degree of rotational freedom compared to their biaryl counterparts. Here we describe a highly efficient catalytic asymmetric synthesis of atropisomeric anilides via Pd(II)-catalyzed atroposelective C-H olefination using readily available L-pyroglutamic acid as a chiral ligand. A broad range of atropisomeric anilides were prepared in high yields (up to 99% yield) and excellent stereoinduction (up to >99% ee) under mild conditions. Experimental studies indicated that the atropostability of those anilide atropisomers toward racemization relies on both steric and electronic effects. Experimental and computational studies were conducted to elucidate the reaction mechanism and rate-determining step. DFT calculations revealed that the amino acid ligand distortion is responsible for the enantioselectivity in the C-H bond activation step. The potent applications of the anilide atropisomers as a new type of chiral ligand in Rh(III)-catalyzed asymmetric conjugate addition and Lewis base catalysts in enantioselective allylation of aldehydes have been demonstrated. This strategy could provide a straightforward route to access atropisomeric anilides, one of the most challenging types of axially chiral compounds.

Asymmetric Synthesis of Β-Lactam Via Palladium-Catalyzed Enantioselective Intramolecular C(sp3)–H Amidation

Synthesis of Chiral Β‐lactams by Pd‐Catalyzed Enantioselective Amidation of Methylene C(sp 3 )–H Bonds

Nucleophile-Dependent Z/ E- and Regioselectivity in the Palladium-Catalyzed Asymmetric Allylic C-H Alkylation of 1,4-Dienes.

Stereoselective Synthesis of Chiral Α‐amino‐β‐lactams Through Palladium(II)‐Catalyzed Sequential Monoarylation/Amidation of C(sp3)H Bonds

Asymmetric Construction of Multifunctional γ-Lactams from 1,3-Dienes and α-Ketoamides via Pd(0)-π-Lewis Base Catalysis

Enantioconvergent Palladium-Catalyzed Alkylation of Tertiary Allylic C-H Bonds.

Enantioselective Synthesis of Sterically Hindered α‐Allyl‐α‐Aryl Lactams via Palladium‐Catalysed Decarboxylative Asymmetric Allylic Alkylation

Enantioconvergent synthesis of axially chiral amides enabled by Pd-catalyzed dynamic kinetic asymmetric aminocarbonylation

Stereoselective construction of β-, γ- and δ-lactam rings via enzymatic C–H amidation

Asymmetric Synthesis of Γ-Lactams Containing Α,β-Contiguous Stereocenters Via Pd(II)-Catalyzed Cascade Methylene C(sp3)–H Alkenylation/Aza-Wacker Cyclization

Enantioselective synthesis of β-aryl-γ-lactam derivatives via Heck–Matsuda desymmetrization of N -protected 2,5-dihydro-1 H -pyrroles

Cooperative Chiral Lewis Base/Palladium‐Catalyzed Asymmetric Syntheses of Methylene‐Containing δ‐Lactams

Enantioselective synthesis of β-aryl-γ-lactam derivatives via Heck–Matsuda desymmetrization of N-protected 2,5-dihydro-1H-pyrroles

Asymmetric 1,n‐Remote Aminoacetoxylation of Unactivated Internal Alkenes Enabled by Palladium Catalysis**

Palladium-catalyzed Sequential Monoarylation/amidation of C(sp3)–H Bonds: Stereoselective Synthesis of Α-Amino-β-lactams and Anti-Α,β-diamino Acid

Enantioselective Synthesis of Atropisomeric Anilides Via Pd(II)-Catalyzed Asymmetric C-H Olefination.

Palladium-Catalyzed Directed Atroposelective C-H Iodination to Synthesize Axial Chiral Biaryl N-Oxides Via Enantioselective Desymmetrization Strategy

Contact damage in model dental multilayers: An investigation of the influence of indenter size

Pd-Catalyzed Intermolecular Carbonylative Dearomatization of Arylamines with Propargylic Acetates for Synthesis of Bridged Polycyclic Lactams

Catalytic, Enantioselective N-acylation of Lactams and Thiolactams Using Amidine-Based Catalysts.

1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial.